NCT04690192 is a Phase 1, PHASE2 clinical trial of CNCT19 in Large B-cell Lymphoma, sponsored by Institute of Hematology & Blood Diseases Hospital, China.

Who is sponsoring NCT04690192?

NCT04690192 is sponsored by Institute of Hematology & Blood Diseases Hospital, China.

What drugs are being tested in NCT04690192?

Interventions in NCT04690192: CNCT19, Gemcitabine Injection, busulfan, Melphalan Injection.

What condition does NCT04690192 study?

NCT04690192 studies Large B-cell Lymphoma.

Is NCT04690192 still recruiting?

NCT04690192 is currently completed. Last updated 13 May 2025.

Last reviewed 2025-05-13 · How we verify

NCT04690192

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Completed Phase 1, PHASE2 Last updated 13 May 2025

What this trial tests

Phase 1, PHASE2 trial testing CNCT19 in Large B-cell Lymphoma in 30 participants. Completed in 30 December 2024.

Timeline

1 January 2021

Primary endpoint
30 December 2023

30 December 2024

Quick facts

Lead sponsor	Institute of Hematology & Blood Diseases Hospital, China
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2021
Primary completion	30 December 2023
Estimated completion	30 December 2024
Sites	1 location across China

Drugs / interventions tested

CNCT19 — full drug profile →
Gemcitabine Injection
busulfan — full drug profile →
Melphalan Injection — full drug profile →

Conditions studied

Large B-cell Lymphoma — all drugs for Large B-cell Lymphoma →

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Who can join

Adults 18 to 65, any sex, with Large B-cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to explore the safety and efficacy of CNCT19 (a second-generation anti-CD19 CAR T-cell using 4-1BB as co-stimulatory domain provided by Juventas, Tianjin, China) infusion following ASCT in patients with relapsed or refractory B-cell lymphoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Liu W, Liu W, Zou H, Chen L, et al · · 2024 · cited 23× · PMID 38631712 · DOI 10.1136/jitc-2024-008857
Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.
Zhao X, Wu J, Zhu X, Xiao Y. · · 2025 · PMID 41137502 · DOI 10.1177/09636897251379571
Bridging transplantation and immunotherapy: Clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy.
Yan Y, Dai Z, Li D, Mao X, et al · · 2025 · PMID 40979669 · DOI 10.21147/j.issn.1000-9604.2025.04.03

Verify or expand the search:

Other recruiting trials for Large B-cell Lymphoma

Currently open trials in the same condition.

NCT07052305 — NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Sub · Phase 1 · recruiting
NCT06919939 — Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma · Phase 2 · recruiting
NCT06994169 — Glofitamab in Real Life · recruiting
NCT07215585 — AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL · Phase 3 · recruiting
NCT07240194 — The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refra · Phase 2 · recruiting

Other Institute of Hematology & Blood Diseases Hospital, China trials

Trials by the same sponsor.

NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04690192 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
Last refreshed: 13 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04690192.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing